Furthermore, the inhibitor blocked TGF-β expression, which suggests these pathways drive HCC proliferation and metastasis through Aha1 and pAkt (Figure 5) (Gao et al., 2023). This evidence concerns the gene AHSA1 and hepatocellular carcinoma.